Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

October 17, 2022

1 minute read

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

Raymond James Maintains Outperform on Everest Re Group, Raises Price Target to $415

February 13, 8:09 AM

Raymond James analyst C. Gregory Peters maintains Everest Re Group (NYSE:RE) with a Outperform and raises the price target from $385 to $415.

December 14, 11:38 AM

Mark Zuckerberg's $100 million compound is located in Hawaii's Kauai Island. The 1,400-acre project is known as Kualoa Ranch.

April 24, 8:11 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often…

March 27, 10:00 AM

Ratings for EastGroup Props (NYSE:EGP) were provided by 5 analysts in the past three months, showcasing a mix…